News & Events
-
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung cancer community, the...
-
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from... -
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to... -
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who... -
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
KRAS Virtual Meetup
Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. After registering, you will receive a confirmation email... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused...
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
HMN 2026: How KRAS(ON) inhibitor zoldonrasib showed effective, durable responses in patients with advanced G12D-mutated lung cancer
HMN 2026: How KRAS(ON) inhibitor zoldonrasib showed effective, durable responses in patients with advanced G12D-mutated lung cancer
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
Elisrasib Shows Clinical Benefit in KRAS G12C Lung Cancer
Title: Elisrasib Shows Clinical Benefit in Advanced NSCLC with KRAS G12C Mutation After Prior Therapy Failure
Title: Elisrasib Shows Clinical Benefit in Advanced NSCLC with KRAS G12C Mutation After Prior Therapy Failure
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
AURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC
AURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer